- Home
- RYN vs ACLX Comparison
RYN vs ACLX Comparison
Compare RYN & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYN
- ACLX
- Stock Information
- Founded
- RYN 1926
- ACLX 2015
- Country
- RYN United States
- ACLX United States
- Employees
- RYN N/A
- ACLX N/A
- Industry
- RYN Real Estate Investment Trusts
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- RYN Real Estate
- ACLX Health Care
- Exchange
- RYN Nasdaq
- ACLX Nasdaq
- Market Cap
- RYN 4.5B
- ACLX 5.3B
- IPO Year
- RYN N/A
- ACLX 2022
- Fundamental
- Price
- RYN $26.73
- ACLX $66.57
- Analyst Decision
- RYN Hold
- ACLX Strong Buy
- Analyst Count
- RYN 3
- ACLX 14
- Target Price
- RYN $33.00
- ACLX $107.67
- AVG Volume (30 Days)
- RYN 876.1K
- ACLX 634.0K
- Earning Date
- RYN 02-05-2025
- ACLX 02-26-2025
- Dividend Yield
- RYN 11.04%
- ACLX N/A
- EPS Growth
- RYN 98.46
- ACLX N/A
- EPS
- RYN 1.07
- ACLX N/A
- Revenue
- RYN $1,004,107,000.00
- ACLX $155,818,000.00
- Revenue This Year
- RYN N/A
- ACLX $12.58
- Revenue Next Year
- RYN N/A
- ACLX N/A
- P/E Ratio
- RYN $24.95
- ACLX N/A
- Revenue Growth
- RYN 20.26
- ACLX 230.33
- 52 Week Low
- RYN $24.88
- ACLX $47.88
- 52 Week High
- RYN $35.29
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- RYN 46.83
- ACLX 32.86
- Support Level
- RYN $24.88
- ACLX $65.38
- Resistance Level
- RYN $26.62
- ACLX $68.24
- Average True Range (ATR)
- RYN 0.59
- ACLX 3.63
- MACD
- RYN 0.25
- ACLX -0.55
- Stochastic Oscillator
- RYN 91.58
- ACLX 16.95
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. The firm also owns timberland in New Zealand. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.